Endometrial cancer trials in United Kingdom

In United Kingdom 26 Also abroad 394

26 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Where
Leicester, London, Sutton
Age
18 years and over
People
600 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07286331 · EU 2025-523362-25-00
Phase 1Taking people
A Study of MGC026 in Participants With Advanced Solid Tumors
Where
Oxford, Sutton
Age
18 years and over
People
394 worldwide
Run by
MacroGenics
See details and how to joinNCT06242470
No phaseTaking people
A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility
Where
Sutton
Age
18 years and over
People
30
Run by
Royal Marsden NHS Foundation Trust
See details and how to joinNCT07675733
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Cambridge, Coventry, London, Nottingham
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Where
Glasgow, London, Manchester
Age
18 years and over
People
542 worldwide
Run by
Artios Pharma Ltd
See details and how to joinNCT04657068
No phaseNot yet taking people in United Kingdom
Protocol for Non-invasive Gynaecological Surveillance in Lynch Syndrome
Where
Edinburgh
Age
18 years and over
People
1,450
Run by
University of Edinburgh
See details and how to joinNCT07877779
Phase 3Taking people
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Where
Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London, Middlesex, Nottingham, Swansea, Truro
Age
18 years and over
People
480 worldwide
Run by
BioNTech SE
See details and how to joinNCT06340568 · EU 2023-507525-42-00
Phase 1/2Taking people
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Where
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
Age
18 years and over
People
245 worldwide
Run by
BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Cambridge, Cardiff, London
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Where
Cambridge, East Sussex, Edinburgh, Glasgow, Leicester, London, Maidstone, Manchester
Age
18 years and over
People
1,123 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06952504 · EU 2024-519331-42-00
Phase 3Taking people
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Where
Bath, Cambridge, Leeds, London, Manchester, Northwood, Taunton
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT06989112 · EU 2023-508056-19-00
Phase 1Taking people
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Where
Manchester
Age
15 years and over
People
282 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT06276491
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Glasgow, Scotland, London, Newcastle upon Tyne
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Cambridge, Glasgow, Scotland, London, Sutton
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
London, Newcastle upon Tyne
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1/2Taking people
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Where
London, Manchester, Oxford, Sutton
Age
18 years and over
People
890 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Cambridge, Dundee, London, Manchester
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 3Taking people
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer
Where
Bath, Cheltenham, Leicester, London, Manchester, Middlesbrough, Oxford, Portsmouth, Southampton, Sutton
Age
18 years and over
People
600
Run by
University College, London
See details and how to joinNCT07831902
Phase 1Taking people
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Where
London
Age
18 years and over
People
156 worldwide
Run by
Context Therapeutics Inc.
See details and how to joinNCT06515613 · EU 2025-523968-20-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 3Taking people
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Where
Bebington, Canterbury, Derby, London, Manchester, Northwood, Truro
Age
18 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT07044336 · EU 2024-518777-34-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
London, Sutton
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Where
Belfast, Cardiff, Glasgow, London, Manchester, Northwood, Preston, Sutton
Age
18 years and over
People
182 worldwide
Run by
Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00
Phase 1Taking people
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Where
Bristol, Edinburgh, Leeds, London, Southampton
Age
18 years and over
People
45
Run by
Epsilogen Ltd
See details and how to joinNCT06547840
No phaseTaking people
Cancer Loyalty Card Study 2 (CLOCS-2)
Where
London
Age
18 years and over
People
2,900
Run by
Imperial College London
See details and how to joinNCT06447064